Generate Biomedicines, a Phase 3 biotech using AI to develop therapies for immunology and oncology, raised $400 million by offering 25 million shares at $16, the midpoint of the range of $15 to $17. Generate Biomedicines states that its AI-enabled Generate...read more
Generate Biomedicines, a Phase 3 biotech using an AI drug discovery platform to develop severe asthma therapies, announced terms for its IPO on Monday. The Somerville, MA-based company plans to raise $400 million by offering 25 million shares at a price range...read more
Updated Monday, 2/23. The typical February lull has taken hold of the IPO market while issuers work on year-end audited financials, but one sizable biotech is scheduled to go public before month end. Small deals may also join the calendar throughout the week. ...read more
Generate Biomedicines, a Phase 3 biotech using an AI drug discovery platform to develop severe asthma therapies, filed on Wednesday with the SEC to raise up to $100 million in an initial public offering. Generate Biomedicines states that its AI-enabled...read more
Asthma-focused AI biotech Generate Biomedicines prices IPO at $16 midpoint
Generate Biomedicines, a Phase 3 biotech using AI to develop therapies for immunology and oncology, raised $400 million by offering 25 million shares at $16, the midpoint of the range of $15 to $17. Generate Biomedicines states that its AI-enabled Generate...read more
Asthma-focused AI biotech Generate Biomedicines sets terms for $400 million IPO
Generate Biomedicines, a Phase 3 biotech using an AI drug discovery platform to develop severe asthma therapies, announced terms for its IPO on Monday. The Somerville, MA-based company plans to raise $400 million by offering 25 million shares at a price range...read more
US IPO Week Ahead: Asthma biotech set to close out February IPO market
Updated Monday, 2/23. The typical February lull has taken hold of the IPO market while issuers work on year-end audited financials, but one sizable biotech is scheduled to go public before month end. Small deals may also join the calendar throughout the week. ...read more
Asthma-focused AI biotech Generate Biomedicines files for a $100 million US IPO
Generate Biomedicines, a Phase 3 biotech using an AI drug discovery platform to develop severe asthma therapies, filed on Wednesday with the SEC to raise up to $100 million in an initial public offering. Generate Biomedicines states that its AI-enabled...read more